ROR2 and gastric cancer: Genomic alterations were noted in ROR1, ROR2, and FOXF1 in more than 4% of samples, whereas WNT5a and NKX2-1 were altered in 2.9% and 1.7%, respectively, in GC patients (Figure 6).